tetano
Editor, Senior Moderator
Clin Respir J
. 2023 Feb 9.
doi: 10.1111/crj.13590. Online ahead of print.
Anti-SARS-CoV-2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients
Chuan-Cai Xu[SUP] 1 [/SUP], Zhi-Song He[SUP] 2 [/SUP], Wei Lei[SUP] 1 [/SUP], Jin-Zhou Zhu[SUP] 3 [/SUP], Da-Guo Zhao[SUP] 4 [/SUP], Jin-Dan Kong[SUP] 4 [/SUP], Yao Wei[SUP] 4 [/SUP], Ying Xu[SUP] 5 [/SUP], Jian-An Huang[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Understanding of the early immune response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections is limited.
Methods: Ninety-eight patients with coronavirus disease 2019 (COVID-19) breakthrough infections were divided into two groups, with intervals from receiving the second dose of inactivated vaccine to the onset of illness <60 or ≥60 days.
Results: The median lymphocyte count and the median anti-SARS-CoV-2 spike immunoglobulin G (IgG) and immunoglobulin M (IgM) titers were higher in the <60-day interval group compared with the corresponding medians in the ≥60-day interval group (p = 0.005, p = 0.001, and p = 0.001, respectively). The median interleukin-6 (IL-6) level in the <60-day interval group was significantly lower than the median IL-6 level in the ≥60-day interval group (p < 0.001).
Conclusions: Our results highlight the different anti-SARS-CoV-2 spike IgG and IgM antibody titers among patients with different intervals from receiving the second dose of inactivated vaccine to the onset of illness.
Keywords: IL-6; SARS-CoV-2; anti-SARS-CoV-2 spike IgG antibody; anti-SARS-CoV-2 spike IgM antibody; inactivated vaccine; lymphocyte.
. 2023 Feb 9.
doi: 10.1111/crj.13590. Online ahead of print.
Anti-SARS-CoV-2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients
Chuan-Cai Xu[SUP] 1 [/SUP], Zhi-Song He[SUP] 2 [/SUP], Wei Lei[SUP] 1 [/SUP], Jin-Zhou Zhu[SUP] 3 [/SUP], Da-Guo Zhao[SUP] 4 [/SUP], Jin-Dan Kong[SUP] 4 [/SUP], Yao Wei[SUP] 4 [/SUP], Ying Xu[SUP] 5 [/SUP], Jian-An Huang[SUP] 1 [/SUP]
Affiliations
- PMID: 36759335
- DOI: 10.1111/crj.13590
Abstract
Background: Understanding of the early immune response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infections is limited.
Methods: Ninety-eight patients with coronavirus disease 2019 (COVID-19) breakthrough infections were divided into two groups, with intervals from receiving the second dose of inactivated vaccine to the onset of illness <60 or ≥60 days.
Results: The median lymphocyte count and the median anti-SARS-CoV-2 spike immunoglobulin G (IgG) and immunoglobulin M (IgM) titers were higher in the <60-day interval group compared with the corresponding medians in the ≥60-day interval group (p = 0.005, p = 0.001, and p = 0.001, respectively). The median interleukin-6 (IL-6) level in the <60-day interval group was significantly lower than the median IL-6 level in the ≥60-day interval group (p < 0.001).
Conclusions: Our results highlight the different anti-SARS-CoV-2 spike IgG and IgM antibody titers among patients with different intervals from receiving the second dose of inactivated vaccine to the onset of illness.
Keywords: IL-6; SARS-CoV-2; anti-SARS-CoV-2 spike IgG antibody; anti-SARS-CoV-2 spike IgM antibody; inactivated vaccine; lymphocyte.